The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.
 
Christos Chouaid
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
Research Funding - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
 
Laura Luciani
Employment - Boehringer Ingelheim; Medtronic
 
Katell Le Lay
Employment - Boehringer Ingelheim
 
Gerard De Pouvourville
Honoraria - Abbvie; Amgen; Bayer; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Edwards Lifesciences; Hopipharm; Ipsen; Janssen; MSD; Myriad Pharmaceuticals; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Edwards Lifesciences; Hopipharm; Ipsen; Janssen; MSD; Myriad Pharmaceuticals; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - Boehringer Ingelheim; Pfizer